Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).

Human gene therapy

Volumn 12, Issue 16, 2001, Pages 2029-2032

  Rasmussen, H ^a   Chu, K W ^a   Campochiaro, P ^a   Gehlbach, P L ^a   Haller, J A ^a   Handa, J T ^a   Nguyen, Q D ^a   Sung, J U ^a  

^a Clinical Research amp Regulatory Affairs   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM DERIVED FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; PROTEIN; SERINE PROTEINASE INHIBITOR;

ADENOVIRUS; AGING; ARTICLE; CLINICAL TRIAL; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RETINA MACULA DEGENERATION;

ADENOVIRIDAE; AGING; EYE PROTEINS; GENE THERAPY; GENETIC VECTORS; HUMANS; MACULAR DEGENERATION; NERVE GROWTH FACTORS; PROTEINS; SERPINS;

EID: 0035514256     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)